Lorviqua Uni Eropa - Slovak - EMA (European Medicines Agency)

lorviqua

pfizer europe ma eeig - lorlatinib - karcinóm, pľúc bez malých buniek - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Latib 400 mg tvrdé kapsuly Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

latib 400 mg tvrdé kapsuly

egis pharmaceuticals plc, maďarsko - imatinib - 44 - cytostatica

Latib 100 mg tvrdé kapsuly Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

latib 100 mg tvrdé kapsuly

egis pharmaceuticals plc, maďarsko - imatinib - 44 - cytostatica